PDCD1 and hepatocellular carcinoma: Dual immune checkpoint inhibition targeting anti-PD-1/PD-L1 and anti-CTLA-4 showed a higher efficacy as compared to monotherapy in the second-line therapy of HCC (Yau et al. 2020; Kelley et al. 2021).